Member Info for tecbadger

Not many private hospitals have NICU wards

Maybe not franchising but reagent rental is a commonly used method by diagnostics companies. Free machine but you have to pay a higher per consumables cost.

Also for the naysayers talking about NHS costs and cutback please google what healthcare economics means. Angles tech will allow for assessment of therapeutic benefit by allowing monitoring by liquid biopsy (with solid tumours monitoring is both extremely more expensive as surgical tissue biopsy costs are much much higher than blood draw and also harmful to the patient. You cant biopsy a lung cancer patient every 3 months)

This can mean therapy switching or cessation depending on the information you get from the tumour across the course of treatment. Also consider that liquid biopsy can catch information both from the primary and any metastatic sites meaning a more complete picture than a single site biopsy.

No i just get bored of rampy b0ll0cks when i do log in. I made a profit on ODX. A fraction of the profit i could have made if i sold earlier but cest la vie

When that stock is not ODX :D

I occasionally revisit this board for posterity. Cant believe the same arguments are happening this far down the line.

ODX really cr@pped the bed

Thx Neutronic

For what its worth i reads this as good news. Im not sure if the clinical trial design has been made public (older posters may have a better idea) however presumably the end points are Progression Free Survival and Overall Survival. In trials like this data is only tended to be released on these metrics once 50% of the patient population reaches end of life.

The safety and tolerability of dose escalation is very promising indeed.

Choo Choooooooooooooooooooooooo........Chug

Remember the heady days of £1.20 its hard to see what they an announce current that will shift the value considerably

Lung cancer is mostly asymptomatic until stage 3 or 4 and so sadly for the majority of cases is only detected then. This partly contributes to it having the lowest 5 year survival rate of any cancer.

With regards to CTCs this is the same for all liquid biopsy cancer testing you just can't guarantee the analyse will be in there even if suspected stage 4. This is widely accepted by the market and liquid biopsies are still massively favourable for repeat testing where invasive tumour biopsy is not possible as frequently.

We will see liquid biopsy really take off for testing in the next 10 years and the single cell analysis will be a key component.

It's like a dog. Put a bit of time and care in up front and you'll be rewarded for years

Choo choooooo.

That RNS was serious p!ss take today

Give them time to profit in UK, EU and where cr mark is accepted first. They can then staff up for FDA which is a whole new level of submission

If there's a lesson in this pandemic it's that to take advantage of the need for diagnostics all you need to do is

1) whack out a product with minimum development and regulatory considerations in as quick a tinine as possible

2) get it through emergency approvals

3) ideally have a few senior figures in government on the payroll. The modern day UK Conservative party were prime for this.

4) sit back and enjoy your profits. The regulatory landscape may change to be more stringent over time but considering the pain involved in switching out a fully trained and implemented product many won't do so.

I suggest the cheapness of the Chinese product also has the skimped in development of the product baked into the cost.

Politics overrode good science at every turn

Surescreen did ok but they are about the only one. Shocking treatment of UK companies by our government. Turns out the sunlit uplands of brexit is really buying cheap rubbish from china

To be fair there were no IIs before this announcement. That's actually a positive that some will be on board

So much for brexit bringing manufacturing jobs to UK owned business

Oooft another 100 million share dilution

Ah look its dribblers corner

Sharebel it's a common method for smaller companies to get product to market within in vitro diagnostics. You get approval based upon a small dataset and then have to keep building that data over time to retain approval.

After 26may the regulations are getting much more stringent with constant analysis and reporting of post market data